EMA Recommends Extension of Therapeutic Indications for Niraparib / Abiraterone Acetate By Ogkologos - February 20, 2026 2 0 Facebook Twitter Google+ Pinterest WhatsApp New combination concerns a combination with ADT for the treatment of adult patients with mHSPC and BRCA1/2 mutations Source RELATED ARTICLESMORE FROM AUTHOR Lisocabtagene Maraleucel Shows Deep, Durable Responses in Patients with Relapsed or Refractory MZL After at Least Two Previous Lines of Systemic Therapy FDA Updates Safety Labelling for Capecitabine and 5-FU on Risks Associated with DPD Deficiency Ultra-Low-Dose Nivolumab Significantly Improves OS Over Chemotherapy in Pretreated Patients with Solid Tumours MOST POPULAR Genetic Risk Score Increases Prediction of Severe Obesity in Adult Survivors... August 5, 2022 ESMO Highlights Key Issues for Patients with Cancer and Their Carers... May 27, 2025 Cannabis, cannabinoids and cancer – the evidence so far September 1, 2021 Having a Heart Attack May Make Breast Cancer Grow Faster August 17, 2020 Load more HOT NEWS Pleural Effusion Emerges as a Negative Prognostic Factor for Immune Checkpoint... Teen Quarterback Scores 8 Touchdowns A Day After His Mom Dies... No EFS Benefit From Adding Atezolizumab To 1-Year BCG Therapy In... Adding Atezolizumab to First-Line Bevacizumab Plus Platinum Regimen Improves Survival in...
